Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Manik Razdan Kuchroo, Robert A. Redd, Jacqueline S. Garcia, Michael Keng, Gabriela S. Hobbs, Jacalyn Rosenblatt, Marlise R. Luskin, Rupa Narayan, Philip C. Amrein, Malgorzata McMasters, Martha Wadleigh, Hanno Hock, Richard Stone, Donna S. Neuberg, David Avigan, Karen K. Ballen, Amir T. Fathi, Daniel J. DeAngelo, Andrew M. Brunner

Blood (2023) 142 (Supplement 1): 2894.

https://doi.org/10.1182/blood-2023-188182

Published: 2023

Journal Articles

Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Matthew J. Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur S. Raje, Daniella Cook, Mahmoud Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika C Banerjee, Anand Rotte, Christopher R Heery, David Avigan, Andrzej J Jakubowiak, Michael R. Bishop

Blood (2023) 142 (Supplement 1): 1023.

https://doi.org/10.1182/blood-2023-189761

Published: 2023

Journal Articles

Phase 1 Trial of Dendritic Cell/AML Fusion Cell Vaccine after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 772.

https://doi.org/10.1182/blood-2023-190832

Published: 2023

Journal Articles

4-1bb Enrichment Enhances Adoptive T Cell Therapy for Hematological Malignancies Using a Novel Approach for Ex Vivo Immune Cell Priming with DC/Tumor Fusion Vaccine

Kathrine S Rallis, Jessica Liegel, Giulia Cheloni, Poorva Bindal, Isabella Saldarriaga, Junyan Zhang, Georges Chedid, Joseph Abirached, John G. Clohessy, Sophia Adamia, Kai W Wucherpfennig, Donald Kufe, Jacalyn Rosenblatt, David Avigan

Blood (2023) 142 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2023-182381

Published: 2023

Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood (2023) 142 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2023-173162

Published: 2023

Journal Articles

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Benjamin A Derman, Jennifer H Cooperrider, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Ajay Major, Theodore Karrison, Ken Jiang, Tadeusz Kubicki, Andrzej J Jakubowiak

Blood (2023) 142 (Supplement 1): 4747.

https://doi.org/10.1182/blood-2023-185309

Published: 2023

Journal Articles

Personal and Shared Tumor-Antigen Prioritization in Diffuse Large B Cell Lymphoma Patients Undergoing CD19 CAR T Cell Treatment

Dimitra Karagkouni, Xanthi Lida Katopodi, Giulia Cheloni, Yuling Ma, Brodie Miles, Gayatri Tiwari, Jenny J. Kim, Mike Mattie, Jacalyn Rosenblatt, David Avigan, Ioannis Vlachos

Blood (2023) 142 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2023-190377

Published: 2023

Journal Articles

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 648.

https://doi.org/10.1182/blood-2023-189940

Published: 2023

Journal Articles

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Blood (2023) 142 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2023-184710

Published: 2023

Journal Articles

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Anthony S. Stein, Ashish Bajel, Shaun Fleming, Mojca Jongen-Lavrencic, Sylvain Garciaz, Abhishek Maiti, Nicolas Boissel, Stephane De Botton, Gerwin A. Huls, David C. de Leeuw, David Avigan, Kyle Jensen, Brigitte Demers, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Andrew H Wei

Blood (2022) 140 (Supplement 1): 7476–7477.

https://doi.org/10.1182/blood-2022-166000

Published: 2022

Journal Articles

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Matthew Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Christine Cornwell, Kamalika Banerjee, Anand Rotte, Christopher R. Heery, David Avigan, Andrzej Jakubowiak, Michael R. Bishop

Blood (2022) 140 (Supplement 1): 7439–7440.

https://doi.org/10.1182/blood-2022-163827

Published: 2022

Journal Articles

G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy

Poorva Bindal, Pavania Elavalakanar, Caitlin A. Trottier, Laura E. Dodge, Emma K. Logan, David J. Sermer, Michael Leukam, Matthew J Weinstock, Robin M. Joyce, Jessica Liegel, Jacalyn Rosenblatt, David Avigan, Carolyn D. Alonso, Jon E. Arnason

Blood (2022) 140 (Supplement 1): 5238–5240.

https://doi.org/10.1182/blood-2022-167976

Published: 2022

Journal Articles

Durable Response to CD19 CAR T Cell Therapy Is Associated with Cytotoxicity and Clonotypic Expansion of the Native T Cell Repertoire

Giulia Cheloni, Dimitra Karagkouni, Yered Pita-Juarez, Daniela Torres, Eleni Kanata, Zachary M. Avigan, Jessica Liegel, Dina Stroopinsky, Brodie Miles, Gayatri Tiwari, Jenny Kim, Mike Mattie, Jacalyn Rosenblatt, David Avigan, Ioannis Vlachos

Blood (2022) 140 (Supplement 1): 644–645.

https://doi.org/10.1182/blood-2022-169230

Published: 2022

Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2022) 140 (Supplement 1): 4834–4838.

https://doi.org/10.1182/blood-2022-162741

Published: 2022

Journal Articles

Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia

Dina Stroopinsky, Anita G. Koshy, Jessica J. Liegel, Myrna Nahas, Giulia Cheloni, Joshua Hauser, Daniela Torres, Poorva Bindal, Maryam Rahimian, Lina Bisharat, Paula Fraenkel, Ozlem Yildirim, Helene Bonnevaux, Stephane Guerif, Donald Kufe, Jacalyn Rosenblatt, David Avigan

Blood (2021) 138 (Supplement 1): 904.

https://doi.org/10.1182/blood-2021-148219

Published: 2021

Journal Articles

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Blood (2021) 138 (Supplement 1): 899.

https://doi.org/10.1182/blood-2021-149659

Published: 2021

Journal Articles

A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Ben A Derman, Ajay Major, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Luis Alcantar, Bernadette M. Libao, Amanda McIver, Evangelia Andreatos, Sarah Major, Brittany Wolfe, Martha Gorski, Theodore G. Karrison, Andrew Stefka, Andrzej Jakubowiak

Blood (2021) 138 (Supplement 1): 2759.

https://doi.org/10.1182/blood-2021-151832

Published: 2021

Journal Articles

Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse

Blood (2021) 138 (Supplement 1): 2830.

https://doi.org/10.1182/blood-2021-154166

Published: 2021

Journal Articles

Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T

Giulia Cheloni, Eleni Kanata, Dina Stroopinsky, Dimitra Karagkouni, Jessica J. Liegel, Daniela Torres, Joshua Hauser, Poorva Bindal, Anita G. Koshy, Yered Pita-Juarez, Adrian Bot, Mike Mattie, Justin Chou, Jacalyn Rosenblatt, David Avigan, Ioannis Vlachos

Blood (2021) 138 (Supplement 1): 2786.

https://doi.org/10.1182/blood-2021-151459

Published: 2021

Journal Articles

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 549.

https://doi.org/10.1182/blood-2021-146060

Published: 2021

NARROW

A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Phase 1 Trial of Dendritic Cell/AML Fusion Cell Vaccine after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia

4-1bb Enrichment Enhances Adoptive T Cell Therapy for Hematological Malignancies Using a Novel Approach for Ex Vivo Immune Cell Priming with DC/Tumor Fusion Vaccine

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Personal and Shared Tumor-Antigen Prioritization in Diffuse Large B Cell Lymphoma Patients Undergoing CD19 CAR T Cell Treatment

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy

Durable Response to CD19 CAR T Cell Therapy Is Associated with Cytotoxicity and Clonotypic Expansion of the Native T Cell Repertoire

Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse

Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only